Skip to main content

Table 2 Univariable and multivariable Cox regression models for the prediction of institutionalization and mortality in SCD/MCI patients

From: Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease

 

Institutionalization

Mortality

Univariable

Model 1

Model 2

Univariable

Model 1

Model 2

 

Age and sex adjusted

 

Without CSF

Without CSF/MRI

 

Age and sex adjusted

 

Without CSF

Without CSF/MRI

Age

1.09*

(1.05; 1.13)

1.10*

(1.06; 1.14)

1.03

(1.00; 1.07)

1.07

(1.02; 1.11)

1.10

(1.06; 1.14)

1.12*

(1.09; 1.16)

1.12*

(1.09; 1.15)

1.04

(1.00; 1.07)

1.06

(1.02; 1.09)

1.08

(1.05; 1.12)

Sex, female

1.21

(0.73; 2.00)

1.35

(0.81; 2.23)

1.52

(0.98; 2.60)

1.67

(1.00; 2.83)

1.56

(0.92; 2.63)

0.72

(0.49; 1.06)

0.75

(0.51; 1.10)

0.97

(0.64; 1.45)

0.96

(0.65; 1.43)

0.88

(0.59; 1.32)

MMSE

0.83*

(0.77; 0.90)

0.83*

(0.76; 0.91)

0.91

(0.83; 1.00)

0.84

(0.77; 0.91)

0.84

(0.77; 0.92)

0.94

(0.88; 1.01)

0.95

(0.88; 1.02)

   

NPI

1.03*

(1.00; 1.06)

1.03*

(1.01; 1.06)

1.03

(1.00; 1.06)

 

1.03

(1.00; 1.06)

1.03*

(1.01; 1.05)

1.02*

(1.00; 1.04)

1.02

(1.00; 1.04)

 

1.02

(1.00; 1.04)

CCI

1.22*

(1.07; 1.39)

1.00

(0.81; 1.23)

   

1.50*

(1.38; 1.63)

1.29*

(1.15; 1.46)

1.27

(1.12; 1.43)

1.23

(1.09; 1.39)

1.28

(1.14; 1.45)

APOE e4

1.96*

(1.18; 3.27)

1.91*

(1.15; 3.19)

 

1.67

(1.00; 2.79)

1.85

(1.10; 3.09)

1.36

(0.94; 1.96)

1.32

(0.91; 1.90)

   

GCA

2.74*

(1.92; 3.92)

2.21*

(1.45; 3.36)

2.08

(1.34; 3.23)

2.08

(1.32; 3.26)

 

2.93*

(2.27; 3.80)

1.89*

(1.39; 2.56)

1.39

(0.97; 1.97)

1.46

(1.03; 2.06)

 

MTA

1.89*

(1.34; 2.58)

1.36

(0.91; 2.04)

   

2.52*

(2.04; 3.12)

1.76*

(1.37; 2.27)

1.50

(1.11; 2.01)

1.44

(1.08; 1.93)

 

WMH

1.60*

(1.20; 2.13)

1.25

(0.91; 1.71)

   

1.47*

(1.19; 1.82)

1.08

(0.85; 1.37)

   

CSF Aβ42a

0.85*

(0.80; 0.90)

0.87*

(0.82; 0.92)

0.90

(0.84; 0.96)

  

0.92*

(0.89; 0.96)

0.95*

(0.92; 0.99)

0.96

(0.92; 1.00)

  

CSF p-tau

1.05*

(1.04; 1.06)

1.04*

(1.02; 1.05)

1.02

(1.01; 1.04)

  

1.03*

(1.02; 1.04)

1.02*

(1.00; 1.03)

1.02

(1.00; 1.03)

  

Harrell’s C

  

0.81

(0.76; 0.86)

0.76

(0.71; 0.82)

0.76

(0.70; 0.82)

  

0.79

(0.75; 0.83)

0.79

(0.75; 0.83)

0.76

(0.71; 0.80)

3-year Brier score

  

0.015

(0.008; 0.021)

0.015

(0.008; 0.021)

0.015

(0.008; 0.021)

  

0.024

(0.016; 0.032)

0.0244

(0.016; 0.032)

0.024

(0.016; 0.032)

  1. Data is represented as Hazard Ratio (95%CI) and Harrell’s C (95%CI)
  2. We used all variables as continuous variables in the models, except for the dichotomous variables gender and APOE e4
  3. AD Alzheimer’s disease, 95%CI 95% confidence interval, NPI Neuropsychiatric Inventory, MMSE Mini-Mental State Examination, CCI Charlson Comorbidity Index, GCA global cortical atrophy, MTA medial temporal lobe atrophy, WMH white matter hyperintensities, CSF cerebrospinal fluid, Aβ42 β-Amyloid 1–42, p-tau Tau phosphorylated at threonine 181
  4. aHazard ratio for every 100 pg/ml
  5. *p<0.05 in univariate analysis
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193